Kyowa Kirin Patent-Cliff Exposure & CMS Drug Spending Portfolio

Kyowa Kirin (US): 3 reconciled FDA prescription therapies (14.8% 2025 to 2030 cliff risk), $354.7M 2024 CMS Part D & Medicaid spend, and 19 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure14.8%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$354.7M
2024 Medicare Part D Spend$108.5M
2024 Medicaid Spend$246.2M
California HCAI SB 17 Filings19 WAC filings (max 21.6% 2-yr change)